AML and MDS Flashcards

1
Q

Different types of AML are diagnosed according to WHO criteria - what do these take into account?

A
  • Morphology
  • Immunophenotype
  • Cytogenetics
  • Molecular findings
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the three major subtypes of AML by the WHO sub-classification?

A
  1. AML with recurrent cytogenetic abnormalities
  2. AML with multi lineage dysplasia (following MDS/MPD or with dysplasia in more than 50% of cells in two lineages)
  3. AML-NOS (classified morphologically)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the difference cytogenetic risk groups in AML?

A
  • Favourable survival = Balanced trans
  • Intermediate survival = Normal karyotype and everything that doesn’t fit into good/poor risk
  • Adverse survival = Complex karyotypes (-5, -7 etc)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are three common acquired abnormalities used for diagnosis of AML? What is their risk?

A
  • t(15;17) in APML
  • t(8;21) in core binding factor AML
  • inv(16) in CBF AML
  • All three fall into the favourable risk group
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Provide details on 3 balanced translocations seen in AML

A
  • t(8;21)(RUNXT1/RUNX1) and inv16 (CBFB/MYH11) generate chimeric proteins of the core binding factor family that orchestrate cellular transcription
  • t(15;17) is cause of APML and the chimeric PML-RARa protein blocks cellular differentiation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are some of the purposes of cytogenetic testing in myeloid malignancies?

A
  • Diagnosis
  • Prognosis
  • Monitoring: Response to treatment, remission/relapse status, loss/return of abnormalities seen at diagnosis, post-BMT look for recipient/donor cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

APML is treated very successfully with what?

A

ATRA (retinoic acid) and arsenic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What type of PCR can be used to detect balanced translocations in diseases such as AML?

A

Nested reverse transcriptase PCR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What two mutations are routinely assayed for in AML?

A
  • FLT3 (receptor tyrosine kinase)

- NPM (nucleophosmin shuttling protein)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Provide some details on FLT3 mutations in AML

A
  • internal tandem duplications confer a poor prognosis (20-30% of cytogenetically normal AML)
  • point mutations (e.g. D835) also occur but clinical impact is less clear (~7% of AML)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Provide some details on NPM mutations in AML

A
  • Mutations in this gene result in the encoded protein being re-localised from the nucleus to the cytoplasm
  • These confer a favourable prognosis
  • 50-60% freq in cytogenetically normal AML
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What assay can be used for both FLT3 internal tandem duplications and NPM1?

A
  • Both are insertion polymorphisms

- can therefore be assayed using fragment analysis on an agarose gel or genetic analyser

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is qPCR used for in the context of diseases such as AML?

A

sequential monitoring of minimum residual disease to predict relapse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Isocitrate dehydrogenase mutations have been found in AML - provide some details

A
  • IDH is a metabolic enzyme which mediated epigenetic modification of DNA
  • Mutations in IDH generate novel protein with enhanced effect on global methylation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the future of mutation testing in AML?

A

NGS gene chip looking at a number of genes relevant to the disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe some key features of myelodysplastic syndromes

A
  • Dysplasia in one or more myeloid precursors
  • Ineffective haematopoiesis
  • Increased apoptosis
  • Peripheral cytopenia (anaemia, neutropenia, thrombocytopenia)
  • May be indolent or aggressive
  • Variable tendency to transform into AML
17
Q

Over 80% of MDS patients will have what type of genetic abnormality?

A
  • Somatic gene mutation
  • Mutated genes involved in wide range of oncogenic and biologically important pathways including epigenetics, transcription, splicing etc.
18
Q

What are the abnormality risk groups associated with myelodysplastic syndrome (MDS)?

A
  • Good: normal, minus Y, del(5q), del(20q)
  • intermediate: other abnormalities
  • Poor: complex (more than 3 anomalies) or chr7 anomalies